Cel Sci's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cel Sci (CVM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cel Sci vs Its Competitors
- Scale: Cel Sci ranks #134 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Cel Sci's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cel sci Corporation | - | - | - | No |
| Competitors combined (8) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CVM Stock Performance relative to its Competitors
CVM Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 2 | Revolution Medicines Inc | 282.9% | Outperformed |
| 3 | Exelixis Inc | 282.9% | Outperformed |
| 4 | Amgen Inc | 282.9% | Outperformed |
| 5 | Gilead Sciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cel Sci's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Cel sci Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Cel sci Corporation |
16.36 | - |
 Amgen Inc |
253,085.12 | 38,095.00 |
 Gilead Sciences Inc |
211,819.32 | 30,988.00 |
 Revolution Medicines Inc |
42,210.35 | 29.51 |
 Incyte Corporation |
24,773.65 | 6,010.75 |
 Exelixis Inc |
18,347.79 | 2,496.86 |
| SUBTOTAL | 554,096.38 | 77,999.62 |
Sign in to see all competitors of Cel sci Corporation.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cel sci Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cel Sci's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Incyte Corporation | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cel Sci's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cel sci Corporation | 16 | - | -378,937 |
| Amgen Inc | 253,085 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 211,819 | 1,822,824 | -227,235 |
| Revolution Medicines Inc | 42,210 | 33,420 | -2,002,588 |
| Incyte Corporation | 24,774 | 2,113,486 | 141,846 |
| Exelixis Inc | 18,348 | 2,176,862 | 1,454,397 |
| PEERS TOTAL | 554,080 | 2,172,994 | 135,680 |
Sign in to see all peers for Cel sci Corporation.
Cel Sci's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Incyte Corporation | United States 92.15 % |
| Exelixis Inc | United States 92.47 % |
| Iovance Biotherapeutics inc | US 98.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cel Sci's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Cel Sci's industry classification, broader than the peer set above. Market cap in millions of $.Cel Sci ranks #134 of 158 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,338, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 253,085 | 25.70 % |
| 2 | Gilead Sciences Inc | 210,465 | 21.38 % |
| 3 | Moderna Inc | 107,062 | 10.87 % |
| 4 | Argenx Se | 63,538 | 6.45 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 134 | Cel sci Corporation | 16 | 0.00 % |
Market cap and industry share for the rest of Cel Sci's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Cel Sci's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 129 | Tevogen Bio Holdings Inc | 22 | - |
| 130 | Tradeup Acquisition Corp | 22 | -84.61 % |
| 131 | Atyr Pharma Inc | 19 | 703.90 % |
| 132 | In8bio Inc | 18 | -43.95 % |
| 133 | Acumen Pharmaceuticals Inc | 1,234 | 12.3% |
| 134 | Cel sci Corporation | 16 | -77.98 % |
| 135 | Jasper Therapeutics Inc | 1,234 | 12.3% |
| 136 | Black Hawk Acquisition Corporation | 1,234 | 12.3% |
| 137 | Dyadic International Inc | 1,234 | 12.3% |
| 138 | Genenta Science S p a | 1,234 | 12.3% |
| 139 | Pluri Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Cel Sci's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Cel Sci's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 2.1x | 5.1x | -3.0x |
| Return on Equity | -2.02 % | industry aggregate | -0.48 % |
| Return on Invested Capital | - | -10.87 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cel Sci's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | - | -70.58 % | -53.32 % | -32.11 % | -40.92 % | -70.84 % | -78.25 % | -75.10 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cel Sci's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Cel Sci falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.5% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Cel Sci's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,338 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Cel Sci's dedicated Suppliers and Customers pages, not here.
Cel Sci's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Cel Sci falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Cel Sci's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Cel Sci's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cel sci Corporation | - | 1.67 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Revolution Medicines Inc | 1.35 | 7.28 | 0.07 |
| Incyte Corporation | 2.40 | 3.83 | - |
| Exelixis Inc | 0.84 | 3.37 | - |
Sign in to see all peers for Cel sci Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cel Sci's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cel sci Corporation | Q2 2026 | - | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Revolution Medicines Inc | Q2 2026 | - | - |
| Incyte Corporation | Q3 2026 | +14.0 % | - |
| Exelixis Inc | Q3 2026 | +10.2 % | -51.1 % |
| PEERS TOTAL | +9.0 % | -28.7 % |
Sign in to see all peers for Cel sci Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cel Sci's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cel sci Corporation | Q2 2026 | - | - |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Revolution Medicines Inc | Q2 2026 | - | -69.3 % |
| Incyte Corporation | Q3 2026 | +9.8 % | -60.7 % |
| Exelixis Inc | Q3 2026 | +41.2 % | +67.9 % |
Sign in to see all peers for Cel sci Corporation.
Cel Sci's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cel sci Corporation | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Revolution Medicines Inc | - | - | - |
| Incyte Corporation | 5.48% | 6.81% | 7.08% |
| Exelixis Inc | 63.88% | 75.01% | 85.83% |
Sign in to see all peers for Cel sci Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cel Sci's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cel sci Corporation | - | - |
| Amgen Inc | 28.90 | 6.64 |
| Gilead Sciences Inc | - | 6.84 |
| Revolution Medicines Inc | - | 1,430.37 |
| Incyte Corporation | 63.82 | 4.12 |
| Exelixis Inc | 29.52 | 7.35 |
| PEERS AVERAGE | 114.04 | 7.10 |
Sign in to see all peers for Cel sci Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.